Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
- PMID: 12473600
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
Abstract
Purpose and experimental design: The purpose is to define intratumoral microvessel density (MVD) and potential biological markers that correlate with inflammatory breast cancer (IBC), we examined MVD, estrogen receptor a (ER) status, MIB-1 proliferation index, p53, and c-erbB-2 by immunohistochemistry in archival specimens from 67 women diagnosed with breast cancer with or without the inflammatory phenotype at the Institut Salah Azaiz (Tunis, Tunisia).
Results: The moderate (25-50/x400 field) to high microvessel count (>50/x400 field) was observed in 23 (51%) of 45 IBC tumors compared with 3 (14%) of 22 non-IBC tumors (P = 0.0031; chi(2) test). The presence of ER was found in 6 (14%) of 44 cases versus 7 (32%) of 22 cases in IBC and non-IBC, respectively (P = 0.10). In this series of 67 patient tumors, the median MVD count in ER-negative breast tumors was 21, whereas the median count was 4 in ER-positive breast tumors (P = 0.08; Wilcoxon rank-sum test). However, MIB-1, p53, and c-erbB-2 were not significantly different between IBC and non-IBC tumors. The intratumoral MVD between IBC and non-IBC was still statistically significant after adjustment for multiple comparisons (P = 0.02; Bonferroni test).
Conclusions: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype.
Comment in
-
Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002.Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3815-6; author reply 3816. Clin Cancer Res. 2003. PMID: 14506176 No abstract available.
Similar articles
-
Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.Clin Cancer Res. 2002 Jun;8(6):1816-21. Clin Cancer Res. 2002. PMID: 12060622 Clinical Trial.
-
Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.J Pathol. 1999 Jan;187(2):207-16. doi: 10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U. J Pathol. 1999. PMID: 10365096
-
Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002.Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3815-6; author reply 3816. Clin Cancer Res. 2003. PMID: 14506176 No abstract available.
-
Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?J Pathol. 2002 Jun;197(2):143-7. doi: 10.1002/path.1072. J Pathol. 2002. PMID: 12015736 Review.
-
[High-throughput quantification of tissue microarrays: identification of candidate target proteins in inflammatory breast cancer].Bull Acad Natl Med. 2007 Feb;191(2):361-74; discussion 374-6. Bull Acad Natl Med. 2007. PMID: 17969554 Review. French.
Cited by
-
Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.PLoS Med. 2014 Sep 9;11(9):e1001720. doi: 10.1371/journal.pmed.1001720. eCollection 2014 Sep. PLoS Med. 2014. PMID: 25202974 Free PMC article.
-
Tailoring Treatment for Patients with Inflammatory Breast Cancer.Curr Treat Options Oncol. 2023 Jun;24(6):580-593. doi: 10.1007/s11864-023-01077-0. Epub 2023 Apr 12. Curr Treat Options Oncol. 2023. PMID: 37043118 Review.
-
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.Clin Cancer Res. 2008 Sep 15;14(18):5893-9. doi: 10.1158/1078-0432.CCR-07-4762. Clin Cancer Res. 2008. PMID: 18794102 Free PMC article.
-
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028757 Free PMC article.
-
First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases.Breast Cancer Res. 2004;6(4):R300-7. doi: 10.1186/bcr790. Epub 2004 Apr 26. Breast Cancer Res. 2004. PMID: 15217496 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous